Using tPA to treat eye hemorrhages after severe eye injuries
Application of tPA in Suprachoroidal and Subretinal Hemorrhage
This study is testing if a special medication can help people with severe eye injuries and bleeding inside the eye feel better and avoid further damage.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT05736757 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the application of tissue plasminogen activator (tPA) for treating severe ocular ruptures that are accompanied by suprachoroidal and subretinal hemorrhages. The study aims to promote the liquefaction of blood clots in these hemorrhages, which can help alleviate elevated intraocular pressure and prevent optic nerve damage. By applying tPA locally in the affected areas, the trial seeks to improve outcomes compared to traditional methods that wait for spontaneous liquefaction. The goal is to enhance the safety and effectiveness of treatment for patients suffering from these serious eye conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with severe ocular rupture accompanied by significant suprachoroidal or subretinal hemorrhage.
Not a fit: Patients with minor ruptures or only small amounts of hemorrhage may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of vision loss and other complications associated with severe ocular hemorrhages.
How similar studies have performed: Previous studies have shown promise in using tPA for similar applications, suggesting potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with severe ocular rupture accompanied by suprachoroidal hemorrhage, or subretinal hemorrhage, or with suprachoroidal hemorrhage and subretinal hemorrhage Exclusion Criteria: * Rupture of eyeball accompanied by a small amount of suprachoroidal hemorrhage or a small amount of subretinal hemorrhage
Where this trial is running
Hangzhou, Zhejiang
- Second Affiliated Hospital, School of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Zhitao Su, Ph.D
- Email: suzhitao@zju.edu.cn
- Phone: 86 0571 87783759
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.